Key Takeaways Axsome's lead drug Auvelity has been the primary driver of top-line growth since its U.S. launch.Auvelity posted $352M in sales in the first nine months of 2025, which increased 77% year over year.Axsome's sNDA for AXS-05 in Alzheimer's disease agitation has an FDA decision set for April 2026.Axsome Therapeutics (AXSM) has been witnessing a strong sales uptake for its lead marketed drug, Auvelity (AXS-05), which is approved for treating major depressive disorder. Since its launch in the United ...